Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.

Lasers Med Sci

Department of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan, 250012, China.

Published: February 2018

We combined pyropheophorbide-a methyl ester, photodynamic therapy (MPPa-PDT), 670 ± 10 nm, 4 mW/cm, with herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV1-TK/GCV) to improve the therapeutic effect. We built HSV1-TK expression vector GV230-TK and we observed a bright green fluorescence under fluorescence microscope. It indicated the recombinant plasmid was transfected into PC-3M prostate cancer cells successfully. As the abundant glucose-regulated protein 78 (GRP78) promoter in PC-3M cells can cause active expression of HSV1-TK, cell protein was collected for western blot to determine the expression of HSV1-TK. In CCK-8 assay (n = 6), the cell survival rate of combined treatment group was about 10%, less than that of pure MPPa-PDT group (23%) and pure HSV1-TK/GCV group (35%) (t test, P < 0.05). Flow cytometry was used to measure the cytotoxicity; the apoptosis rate of combined treatment group was about 38%, higher than that of pure MPPa-PDT group (about 22%) and pure HSV1-TK/GCV group (about 19%). The results showed that the combination of the two treatments can effectively improve the cytocidal effect in PC-3M cells.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10103-017-2331-6DOI Listing

Publication Analysis

Top Keywords

prostate cancer
8
expression hsv1-tk
8
combination mppa-pdt
4
mppa-pdt hsv1-tk/gcv
4
hsv1-tk/gcv gene
4
gene therapy
4
therapy prostate
4
cancer combined
4
combined pyropheophorbide-a
4
pyropheophorbide-a methyl
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!